Tonix Pharmaceuticals Holding (TNXP) Income towards Parent Company (2011 - 2026)

Tonix Pharmaceuticals Holding has reported Income towards Parent Company for 16 years, with the latest figure at -$41.1 million in Q2 2026.

• On a quarterly basis, Income towards Parent Company fell 50.27% year-over-year to -$41.1 million in Q2 2026; TTM through Jun 2026 was -$160.1 million, a 96.15% decrease from a year earlier, with the FY2025 full-year figure at -$121.6 million, up 11.8% from the prior year.
• Income towards Parent Company was -$41.1 million for Q2 2026 at Tonix Pharmaceuticals Holding, down from -$40.2 million in the prior quarter.
• The five-year high for Income towards Parent Company was -$15.7 million in Q1 2025, with the low at -$77.3 million in Q2 2024.
• Average Income towards Parent Company over 5 years is -$31.5 million, with a median of -$28.5 million recorded in 2022.
• The sharpest annual moves came in 2024 and 2025: Income towards Parent Company slumped 166.59% in 2024, then soared 64.62% in 2025.
• Over 5 years, Income towards Parent Company stood at -$31.7 million in 2022, then grew by 15.77% to -$26.7 million in 2023, then rose by 14.71% to -$22.8 million in 2024, then tumbled by 106.26% to -$46.9 million in 2025, then rose by 12.44% to -$41.1 million in 2026.
• The last three Income towards Parent Company figures came in at -$41.1 million (Q2 2026), -$40.2 million (Q1 2026), and -$46.9 million (Q4 2025), per Business Quant data.